PRimary Care Opioid Use Disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment
-
Published:2021-01-31
Issue:1
Volume:16
Page:
-
ISSN:1940-0640
-
Container-title:Addiction Science & Clinical Practice
-
language:en
-
Short-container-title:Addict Sci Clin Pract
Author:
Campbell Cynthia I.ORCID, Saxon Andrew J., Boudreau Denise M., Wartko Paige D., Bobb Jennifer F., Lee Amy K., Matthews Abigail G., McCormack Jennifer, Liu David S., Addis Megan, Altschuler Andrea, Samet Jeffrey H., LaBelle Colleen T., Arnsten Julia, Caldeiro Ryan M., Borst Douglas T., Stotts Angela L., Braciszewski Jordan M., Szapocznik José, Bart Gavin, Schwartz Robert P., McNeely Jennifer, Liebschutz Jane M., Tsui Judith I., Merrill Joseph O., Glass Joseph E., Lapham Gwen T., Murphy Sean M., Weinstein Zoe M., Yarborough Bobbi Jo H., Bradley Katharine A.
Abstract
Abstract
Background
Most people with opioid use disorder (OUD) never receive treatment. Medication treatment of OUD in primary care is recommended as an approach to increase access to care. The PRimary Care Opioid Use Disorders treatment (PROUD) trial tests whether implementation of a collaborative care model (Massachusetts Model) using a nurse care manager (NCM) to support medication treatment of OUD in primary care increases OUD treatment and improves outcomes. Specifically, it tests whether implementation of collaborative care, compared to usual primary care, increases the number of days of medication for OUD (implementation objective) and reduces acute health care utilization (effectiveness objective). The protocol for the PROUD trial is presented here.
Methods
PROUD is a hybrid type III cluster-randomized implementation trial in six health care systems. The intervention consists of three implementation strategies: salary for a full-time NCM, training and technical assistance for the NCM, and requiring that three primary care providers have DEA waivers to prescribe buprenorphine. Within each health system, two primary care clinics are randomized: one to the intervention and one to Usual Primary Care. The sample includes all patients age 16–90 who visited the randomized primary care clinics from 3 years before to 2 years after randomization (anticipated to be > 170,000). Quantitative data are derived from existing health system administrative data, electronic medical records, and/or health insurance claims (“electronic health records,” [EHRs]). Anonymous staff surveys, stakeholder debriefs, and observations from site visits, trainings and technical assistance provide qualitative data to assess barriers and facilitators to implementation. The outcome for the implementation objective (primary outcome) is a clinic-level measure of the number of patient days of medication treatment of OUD over the 2 years post-randomization. The patient-level outcome for the effectiveness objective (secondary outcome) is days of acute care utilization [e.g. urgent care, emergency department (ED) and/or hospitalizations] over 2 years post-randomization among patients with documented OUD prior to randomization.
Discussion
The PROUD trial provides information for clinical leaders and policy makers regarding potential benefits for patients and health systems of a collaborative care model for management of OUD in primary care, tested in real-world diverse primary care settings.
Trial registration # NCT03407638 (February 28, 2018); CTN-0074 https://clinicaltrials.gov/ct2/show/NCT03407638?term=CTN-0074&draw=2&rank=1
Funder
National Institute on Drug Abuse
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2018 National Survey on Drug Use and Health. 2019. https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHNationalFindingsReport2018/NSDUHNationalFindingsReport2018.pdf. Accessed 6 July 2020. 2. Williams AR, Nunes EV, Bisaga A, Levin FR, Olfson M. Development of a cascade of care for responding to the opioid epidemic. Am J Drug Alcohol Abuse. 2019;45(1):1–10. 3. Crowley R, Kirschner N, Dunn AS, Bornstein SS & Health, Public Policy Committee of the American College of P. Health and public policy to facilitate effective prevention and treatment of substance use disorders involving illicit and prescription drugs: an American College of Physicians position paper. Ann Intern Med. 2017;166(10):733–6. 4. Dunlap B, Cifu AS. Clinical management of opioid use disorder. JAMA. 2016;316(3):338–9. 5. U.S. Department of Health and Human Services, Office of the Surgeon General. Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health. Washington, DC: U.S. Department of Health & Human Services; 2016.
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|